Table 4 Surgical management of the patients treated for acute cholecystitis during the COVID-19 pandemic comparing those who survived (n = 2482) and those who died (n = 64);
Variable | Alive, n = 2482 | Dead, n = 64 | p |
|---|---|---|---|
Surgical treatment | < 0.001 | ||
Conservative | 335 (13.6%) | 9 (14.1%) | |
Conservative and delayed Laparoscopic Cholecystectomy | 290 (11.7%) | 4 (6.3%) | |
ERCP ± sphincterotomy and delayed laparoscopic cholecystectomy | 173 (7%) | 0 (0%) | |
Cholecystostomy/percutaneous drainage | 180 (7.3%) | 15 (25%) | |
Urgent laparoscopic cholecystectomy | 1293 (52.1%) | 20 (23.4%) | |
Urgent open cholecystectomy | 200 (8.1%) | 64 (31.3%) | |
Delay in treatment (hours) | 49.84 (SD 109.6) | 37.10 (SD 58.6) | |
Adequate source control | 2285 (95.1%) | 54 (87.1%) | < 0.001 |
Adequate empirical antibiotics | 2396 (98%) | 169 (95.5%) | < 0.001 |
Postoperative Complications | 302 (12.2%) | 37 (59.7%) | < 0.001 |
Hospital stay (days) | 6.8 (6.2) | 13.91 (14.04) | < 0.001 |